Encorafenib in Combination With Binimetinib (Braftovi and Mektovi)

Messages clés

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses encorafenib (Braftovi), 75 mg oral capsules in combination with binimetinib (Mektovi), 15 mg oral tablets.
• Indications:
  • Braftovi (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.
  • Mektovi (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.